Plain-English translation of NCT06741553 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Alzheimer Disease research guide →This is an observational study tracking patients with early Alzheimer's disease or mild cognitive impairment who are being treated with lecanemab. Researchers want to see how the medication affects brain imaging, thinking and memory skills, and what side effects people might experience. The study will follow patients over time with brain scans, blood tests, and thinking assessments.
While this medication has been shown to help with early Alzheimer's in controlled trials, doctors need real-world information about how well it works for different patients, how safe it is long-term, and what factors might make someone more likely to have side effects.
You likely qualify if…
You likely don't qualify if…
You would continue receiving lecanemab treatment (which you are already choosing to do) while the research team monitors you over time. At regular visits, you'll have brain MRI scans, blood tests, and cognitive assessments (thinking and memory tests). Researchers will track how your brain looks on imaging, whether your thinking improves, and watch carefully for any side effects from the medication.
AI-generated summary from trial data · Jun 19, 2026 · Not medical advice
China